Abstract. Breast cancer represents the most commonly diagnosed female malignancy worldwide. Although breast cancer screening and treatments have improved significantly over the last half-century, ...
AbstractBackground:. Rinatabart sesutecan (Rina-S) is an investigational antibody-drug conjugate composed of a human monoclonal antibody that selectively binds to folate receptor alpha (FRα), a novel ...
AbstractBackground:. JS107 is a monomethyl auristatin E conjugated, CLDN18.2 specific ADC. JS107 exhibited potent anti-tumor activities in preclinical studies with a tolerable safety profile. Here we ...
Background: The current standard of care for patients (pts) with treatment-naive Stage II–III triple-negative breast cancer (TNBC) is neoadjuvant pembrolizumab ...
Introduction: Engineered cell therapies have demonstrated significant clinical activity against hematologic malignancies, but responses have been rare in solid tumors. Our previously developed human ...
AbstractIntroduction and Objectives:. 2141-V11 is a novel anti-CD40 antibody developed by our group, with enhanced binding to FcγRIIB that results in effective tumor-specific T-cell responses in vivo ...
Introduction: There is a need for ADC payloads with an improved therapeutic index, consequently we have coupled potent and selective inhibitors of NMT to trastuzumab to test their potential in both in ...
Mol Cancer Ther (2025) 24 (10_Supplement): B130. Deruxtecan (DXd)-based antibody drug conjugates (ADCs) have demonstrated remarkable efficacy across a range of cancers in preclinical and clinical ...
Cancer Res (2024) 84 (7_Supplement): LB179. Breast cancer remains an unmet medical need. It has become the most occurring and deadliest cancer for women globally. Estrogen receptor (ER) is expressed ...
Abstract. ADAM9 (A Disintegrin And Metalloproteinase 9) is a transmembrane metalloproteinase overexpressed in a wide range of solid tumors, where it promotes tumor progression, metastasis, and poor ...
AbstractPoly (ADP-ribose) polymerase inhibitors (PARPi) are a first-line treatment for patients with epithelial ovarian cancer (EOC), but the development of resistance limits long-term therapeutic ...
Abstract. Brentuximab vedotin (ADCETRIS®) is an antibody-drug conjugate (ADC) directed against CD30. It consists of an anti-CD30 monoclonal antibody conjugated to monomethyl auristatin E (MMAE), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results